Skip to main content
SpringerLink
Log in

Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB Trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE)

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

An Erratum to this article was published on 28 January 2012

Abstract

Introduction

The number of patients with both hypertension and obesity has been increasing in Japan. Many of these patients may also have insulin resistance. Telmisartan, an angiotensin II receptor blocker (ARB), selectively activates peroxisome proliferatoractivated receptor (PPAR)-gamma, and this effect is considered to markedly improve insulin resistance in obese patients with hypertension. We compared the antihypertensive and insulin resistance-improving effects of telmisartan with those of candesartan and valsartan in this patient population.

Methods

Twenty-eight elderly patients with an average body mass index (BMI) of 27.1 kg/m2 were enrolled in this 6-month study. Patients were randomly selected to either switch from candesartan or valsartan to telmisartan or to continue with their current ARB. A 75 g oral glucose tolerance test (OGTT) was performed before and after switching, and the effect of telmisartan on the insulin response to glucose loading was investigated.

Results

There was no significant difference in blood pressure between the two groups after drug administration, but glucose tolerance significantly improved in the telmisartan group. The hyperinsulin response to glucose loading also significantly improved in those taking telmisartan, as well as homeostasis model assessment of insulin resistance (HOMA-IR). These changes were not observed in the control group.

Conclusion

In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading. Telmisartan may therefore be beneficial in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gallagher EJ, LeRoith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010;77:511–523.

    Article  PubMed  Google Scholar 

  2. Addison S, Stas S, Hayden MR, Sowers J. Insulin resistance and blood pressure. Curr Hypertens Rep. 2008;10:319–325.

    Article  PubMed  CAS  Google Scholar 

  3. Chapman MJ, Sposito AC. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol Ther. 2008;117:354–373.

    Article  PubMed  CAS  Google Scholar 

  4. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2231.

    Article  PubMed  CAS  Google Scholar 

  5. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008;51:393–398.

    Article  PubMed  CAS  Google Scholar 

  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.

    Article  Google Scholar 

  7. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res. 2009;32:826–834.

    Article  PubMed  CAS  Google Scholar 

  8. Benson SC, Pershadsingh HA, Ho CI, et al. Hypertension: identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993–1002.

    Article  PubMed  CAS  Google Scholar 

  9. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care. 2005;28:498.

    Article  PubMed  Google Scholar 

  10. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.

    Article  PubMed  Google Scholar 

  11. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25 841–848.

    Article  PubMed  CAS  Google Scholar 

  12. Davis TME. Ethnic diversity in type 2 diabetes. Diabet Med. 2008;25(suppl. 2):52–56.

    Article  PubMed  Google Scholar 

  13. Takeuchi M, Okamoto K, Takagi T, Ishii H. Ethnic difference in patients with type 2 diabetes mellitus in inter-East Asian populations: a systematic review and meta-analysis focusing on fasting serum insulin. Diabetes Res Clin Pract. 2008;81:370–376.

    Article  PubMed  CAS  Google Scholar 

  14. Examination Committee of Criteria for “Obesity Disease” in Japan, Japan Society for the Study of Obesity. New criteria for “obesity disease” in Japan. Circ J. 2002;66:987–992

    Article  Google Scholar 

  15. Ohnishi H, Saitoh S, Takagi S, et al. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu study. Diabetes Obes Metab. 2005;7:83–87.

    Article  PubMed  CAS  Google Scholar 

  16. Japan Diabetes Society. Treatment Guide for Diabetes 2007. Tokyo: Bunkodo Co. Ltd.

    Google Scholar 

  17. Fogari R, Zoppi A, Ferrari I, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41:893–898.

    Article  PubMed  CAS  Google Scholar 

  18. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas. 2010;65:315–319.

    Article  PubMed  CAS  Google Scholar 

  19. de Luis DA, Conde R, González-Sagrado M, et al. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp. 2010;25:275–279.

    PubMed  Google Scholar 

  20. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9:203–210.

    Article  PubMed  Google Scholar 

  21. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.

    Article  Google Scholar 

  22. US Food and Drug Administration web site. Micardis(telmisartan) cardiovascular and renal drugs advisory committee briefing document. July 29, 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM173529.pdf. Accessed February 2011.

  23. European Medicines Agency web site. Assessment report for Micardis. November 23, 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000209/WC500073444.pdf. Accessed February 2011.

  24. Nakagami H, Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Curr Vasc Pharmacol. 2011;9:162–166.

    Article  PubMed  CAS  Google Scholar 

  25. Nakagami H, Kiomy Osako M, Nakagami F, et al. Prevention and regression of nonalcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med. 2010;26:477–481.

    PubMed  CAS  Google Scholar 

  26. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183.

    Article  Google Scholar 

  27. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61.

    Article  PubMed  Google Scholar 

  28. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477–1490.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 4-11-1 Izumihonmachi, Komae City, Tokyo, Japan

    Yutaka Mori

  2. Department of Clinical Research, National Hospital Organization, Utsunomiya National Hospital, Utsunomiya City, Tochigi, Japan

    Yutaka Mori & Takaaki Tanaka

  3. Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Komae City, Tokyo, Japan

    Kenichi Matsuura, Junichi Yokoyama & Kazunori Utsunomiya

Authors
  1. Yutaka Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaaki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenichi Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junichi Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazunori Utsunomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yutaka Mori.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s12325-011-0089-y.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, Y., Tanaka, T., Matsuura, K. et al. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB Trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Therapy 28, 698–706 (2011). https://doi.org/10.1007/s12325-011-0040-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0040-2

Keywords

Search

Navigation